Octant Patents

Patent portfolio assigned to Octant (verified via public assignee records). Identified as Octant Bio (Emeryville, CA) - synthetic-biology polypharmacology drug discovery (GPCR-focused), a16z-backed. Bristol Myers Squibb is both an investor and a drug-discovery partner (inflammation pathways). Google Patents shows WO2020243164A1 (transcriptional relay system) assigned to Octant, Inc. Competitors are broader AI-drug-discovery peers (loose comparison).